XOMAO — XOMA Royalty Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 791908 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 310,000 | — | -480,000 | 4,465,000 | 271,858,000 | 85,600,000 | 158,963,000 |
| Dec 2025 | 1,432,000 | — | 2,182,000 | 6,103,000 | 272,698,000 | 82,908,000 | 188,757,000 |
| Sep 2025 | 532,000 | — | -1,330,000 | 14,051,000 | 263,151,000 | 45,189,000 | 155,194,000 |
| Jun 2025 | 5,379,000 | — | 4,603,000 | 9,191,000 | 223,456,000 | 75,060,000 | 131,002,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,871,000
Investing CF
$50,886,000
Financing CF
$-26,463,000
CapEx
$-114,000
Dividends Paid
$-5,472,000
Buybacks
$-16,715,000
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,221,450,000
Inventory
—
Receivables
$27,676,000
ST Investments
$382,000
EBIT TTM
$44,846,000
Pretax Income TTM
$31,815,000
Interest Exp TTM
$13,031,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$48,555,000
EBITDA
$8,295,000
Free Cash Flow
$-13,069,500
Enterprise Value
$376,307,584
Total Cash
$86,094,000
Total Debt
$124,732,000
Shares Out
—
Trailing EPS
$1.00
Book Value
$7.07
ROE
34.2%
ROA
1.3%
Div Yield
8.27%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,660,000 | 11,384,000 | 31,712,000 | 272,698,000 | 188,757,000 | — | 2,871,000 |
| Dec 2024 | 10,220,000 | -39,976,000 | -13,821,000 | 221,277,000 | 159,375,000 | — | -13,748,000 |
| Dec 2023 | 4,758,000 | -23,463,000 | -40,831,000 | 234,301,000 | 145,580,000 | — | -18,158,000 |
| Dec 2022 | 6,027,000 | -17,414,000 | -17,104,000 | 140,382,000 | 16,368,000 | — | -12,879,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
2026-04-27 20:11 · Yahoo
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
2026-04-27 11:00 · Yahoo
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
2026-03-26 10:51 · Yahoo
XOMA Royalty Q4 Earnings Call Highlights
2026-03-18 23:20 · Yahoo
XOMA Royalty Declares Quarterly Preferred Stock Dividends
2026-03-18 20:30 · Yahoo
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
2026-03-18 10:00 · Yahoo
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
2026-03-12 10:30 · Yahoo
XOMA Royalty to Present at Investor Conferences in March
2026-02-18 21:30 · Yahoo
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
2026-02-09 14:53 · Yahoo
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses
2026-01-18 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.